201 related articles for article (PubMed ID: 24559430)
41. Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data.
Knoll GA; Kokolo MB; Mallick R; Beck A; Buenaventura CD; Ducharme R; Barsoum R; Bernasconi C; Blydt-Hansen TD; Ekberg H; Felipe CR; Firth J; Gallon L; Gelens M; Glotz D; Gossmann J; Guba M; Morsy AA; Salgo R; Scheuermann EH; Tedesco-Silva H; Vitko S; Watson C; Fergusson DA
BMJ; 2014 Nov; 349():g6679. PubMed ID: 25422259
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Ruenroengbun N; Sapankaew T; Chaiyakittisopon K; Phoompoung P; Ngamprasertchai T
Front Cell Infect Microbiol; 2022; 12():865735. PubMed ID: 35433502
[TBL] [Abstract][Full Text] [Related]
43. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis.
Molnar AO; Fergusson D; Tsampalieros AK; Bennett A; Fergusson N; Ramsay T; Knoll GA
BMJ; 2015 Jun; 350():h3163. PubMed ID: 26101226
[TBL] [Abstract][Full Text] [Related]
44. Interleukin 2 receptor antagonists for kidney transplant recipients.
Webster AC; Ruster LP; McGee R; Matheson SL; Higgins GY; Willis NS; Chapman JR; Craig JC
Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD003897. PubMed ID: 20091551
[TBL] [Abstract][Full Text] [Related]
45. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome.
von Groote TC; Williams G; Au EH; Chen Y; Mathew AT; Hodson EM; Tunnicliffe DJ
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004293. PubMed ID: 34778952
[TBL] [Abstract][Full Text] [Related]
46. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
[TBL] [Abstract][Full Text] [Related]
47. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
Deng J; Lu Y; He L; Ou J; Xie H
Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
[TBL] [Abstract][Full Text] [Related]
48. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
49. Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients.
Funch DP; Brady J; Ko HH; Dreyer NA; Walker AM
Recent Results Cancer Res; 2002; 159():81-8. PubMed ID: 11785847
[TBL] [Abstract][Full Text] [Related]
50. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
Pascual J
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
[TBL] [Abstract][Full Text] [Related]
51. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
52. Immunosuppressive therapy for kidney transplantation in children and adolescents: systematic review and economic evaluation.
Haasova M; Snowsill T; Jones-Hughes T; Crathorne L; Cooper C; Varley-Campbell J; Mujica-Mota R; Coelho H; Huxley N; Lowe J; Dudley J; Marks S; Hyde C; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(61):1-324. PubMed ID: 27557331
[TBL] [Abstract][Full Text] [Related]
53. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
T A M; Chng R; Yau WP
Ann Transplant; 2021 Dec; 26():e933588. PubMed ID: 34963678
[TBL] [Abstract][Full Text] [Related]
55. Hepatitis C virus related lymphoproliferative disorder in a renal transplant recipient.
Aravindan AN; Moger V; Sakhuja V; Kohli HS; Varma N; Jha V
Int Urol Nephrol; 2006; 38(2):355-7. PubMed ID: 16868710
[TBL] [Abstract][Full Text] [Related]
56. Very late onset lymphoproliferative disorders occurring over 10 years post-renal transplantation: PTLD.Int. Survey.
Khedmat H; Taheri S
Hematol Oncol Stem Cell Ther; 2011; 4(2):73-80. PubMed ID: 21727768
[TBL] [Abstract][Full Text] [Related]
57. The incidence of non-melanoma skin cancer and post-transplant lympho-proliferative disorders in the Scottish cardiac transplant population and the provision of specialist dermatological follow-up.
McPherson I; Kirk A
Scott Med J; 2018 Feb; 63(1):3-10. PubMed ID: 29073846
[TBL] [Abstract][Full Text] [Related]
58. Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.
Mellon L; Doyle F; Hickey A; Ward KD; de Freitas DG; McCormick PA; O'Connell O; Conlon P
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD012854. PubMed ID: 36094829
[TBL] [Abstract][Full Text] [Related]
59. Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta).
Page EK; Courtney CL; Sharma P; Cheeseman J; Jenkins JB; Strobert E; Knechtle SJ
Exp Toxicol Pathol; 2013 Nov; 65(7-8):1019-24. PubMed ID: 23578881
[TBL] [Abstract][Full Text] [Related]
60. Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.
Brook MO; Hester J; Petchey W; Rombach I; Dutton S; Bottomley MJ; Black J; Abdul-Wahab S; Bushell A; Lombardi G; Wood K; Friend P; Harden P; Issa F
BMJ Open; 2022 Apr; 12(4):e061864. PubMed ID: 35428650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
